In TRIUMPH-1, a phase 3 trial of adults with obesity, people on the highest 12 mg weekly dose lost an average of 28.3% of their body weight over 80 weeks, compared with 2.2% on placebo, according to Eli Lilly’s topline results as of October 2026. Counting everyone who started the trial, including people who stopped early, the average was 25%.
Retatrutide is an investigational once-weekly injection. Scientific American explains that Ozempic (semaglutide) targets one hormone receptor, GLP-1, and Mounjaro (tirzepatide) targets two, GLP-1 and GIP. Retatrutide targets three: GLP-1, GIP and glucagon. That is why it is often grouped with newer weight-loss drugs.
How much weight did people lose in each retatrutide trial?
The trials below are the ones reported so far. Each one measured a different group of people for a different length of time, so the percentages are not interchangeable.
| Trial | Who was in it | Length | Average loss on the highest dose |
|---|---|---|---|
| Phase 2 obesity trial, presented at the 2023 ADA meeting | 338 adults with obesity who did not have type 2 diabetes | 48 weeks | 24.2% on 12 mg, versus 2.1% on placebo |
| Phase 2 type 2 diabetes trial | 281 adults with type 2 diabetes | 36 weeks | Almost 17% on 8 mg and 12 mg |
| TRIUMPH-1 (phase 3) | 2,339 adults with overweight or obesity | 80 weeks | 28.3% on 12 mg, versus 2.2% on placebo |
| TRIUMPH-2 (phase 3) | 1,152 adults with obesity and type 2 diabetes | 80 weeks | More than 20% on 12 mg (an average of 49.6 lb, or 22.5 kg) |
| TRIUMPH-4 (phase 3) | Adults with overweight or obesity and knee osteoarthritis | 68 weeks | Up to 28.7% |
The phase 2 obesity results appear in a meta-analysis of three randomized trials published in PubMed Central, which reports 24.2% at 48 weeks on 12 mg. The phase 2 type 2 diabetes figure comes from Dr. Julio Rosenstock’s report at the ADA meeting, which said weight loss of almost 17% was reached at week 36 without a plateau.
Healio’s coverage of TRIUMPH-1 reports the numbers from Eli Lilly’s topline release, which the company announced in May 2026. Healio describes retatrutide as an investigational drug under study for obesity. The full TRIUMPH-1 results were published in the New England Journal of Medicine in September 2026, according to Scientific American’s report on the trials.
Does a higher dose mean more weight loss on retatrutide?
In TRIUMPH-1, yes. The bigger the dose, the larger the average loss, as the table shows. Healio reports two ways of calculating the same trial. The efficacy estimand, the 28.3% headline figure, generally uses data from people who stayed on treatment. The treatment-regimen estimand counts everyone who started, and it is a close relative of intention-to-treat analysis (our research library), the method that keeps people in their original groups.
| TRIUMPH-1 group (weekly) | Efficacy estimand, 80 weeks | Treatment-regimen estimand, 80 weeks |
|---|---|---|
| Retatrutide 4 mg | 19% | 17.6% |
| Retatrutide 9 mg | 25.9% | 23.7% |
| Retatrutide 12 mg | 28.3% | 25% |
| Placebo | 2.2% | 3.9% |
Averages hide a wide spread. Healio reports that 45.3% of people on 12 mg had a 30% or greater weight loss at 80 weeks in TRIUMPH-1. Dr. Ania Jastreboff, the lead investigator, said that people with severe obesity on the highest dose lost, on average, 30% of their body weight over two years. That is a subgroup, not the whole trial.
How much weight did people with type 2 diabetes lose on retatrutide?
Less than people without diabetes, in the trials reported so far. In TRIUMPH-2, the 12 mg group lost more than 20% of body weight on average, while the placebo group lost 9.3 pounds (4.2 kg). Scientific American quotes Randy Seeley of the University of Michigan, who was not involved in the trial, saying that people with type 2 diabetes tend to lose less weight on GLP-1 drugs than people without diabetes do. The meta-analysis makes the same point about anti-obesity medicines in general.
What did the pooled analysis find?
A meta-analysis of three randomized trials, with 640 patients who had overweight, obesity and/or type 2 diabetes, compared once-weekly retatrutide with placebo. Retatrutide reduced body weight by an average of 10.66 kg in the pooled analysis, a significant reduction in favor of retatrutide over placebo. This is a pooled figure from mostly early trials, so it is lower than the 80-week phase 3 averages above. The authors note that the trials had short follow-up and that weight loss had not levelled off, so larger losses may appear with longer studies.
How long did the weight loss last on retatrutide?
The trials followed people for 36 to 104 weeks, so the reported results are long-run averages, not one-month numbers. In the phase 2 obesity trial, the 12 mg group had lost 17.5% at 24 weeks, compared with 1.6% on placebo, according to the meta-analysis. In the TRIUMPH-1 extension, people who started on 12 mg had lost 30.3% from baseline by week 104. That figure covers only the extension participants, and the placebo group that switched to retatrutide reached 19.2%.
What is not known about retatrutide weight loss yet?
Retatrutide is not yet approved, so the figures come from trials, not from people using an approved prescription. Scientific American notes that phase 3 trials are the step regulators look at when deciding on approval. The Cleveland Clinic’s overview of GLP-1 medicines lists semaglutide and high-dose liraglutide as FDA-approved options for obesity.
Side effects matter for the numbers too. In TRIUMPH-1, 11.3% of people on 12 mg stopped treatment because of side effects, compared with 4.9% on placebo. Healio lists nausea, diarrhea, constipation, vomiting and upper respiratory infection as the most common side effects, with dysesthesia (an abnormal skin sensation) and urinary tract infections more common than on placebo. Healio’s expert perspective adds that predictable reductions in skeletal muscle and bone may occur with this degree of weight loss, particularly over the long term.
Where to go next
If you are comparing retatrutide with medicines you can use now, read the best mounjaro alternatives for weight loss. For the broader picture of hormones and weight, see weight, hormones and body health.
Before you go: questions to bring to a clinician
- Ask whether retatrutide is approved yet, and what you could use now that is approved for your situation.
- Read the TRIUMPH-1 New England Journal of Medicine paper for the full figures, including side effects and dropouts.
- If you are considering any weight-loss medicine, talk with a clinician who can review your health history and weight goals.
By The Nerve & Joint Pain Desk Editorial Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.

